openbell openbell

Financial news scored by AI. No noise, no delay. Latest: Equinix Reports Strong Q3 Results, Raises 2026 Guidance, and Announces $700 Million Stock Offering (Impact: +55). OpenBell scores breaking market news for potential price impact, so you can see why it matters, not just that it happened.

Financial News with AI Impact Scores

Get real-time financial news with AI-powered impact analysis delivered through Discord

Today's Market Overview

openbell provides real-time news intelligence for smarter trades. Latest stories cover Real Estate, Healthcare sectors. Top story: "Equinix Reports Strong Q3 Results, Raises 2026 Guidance, and Announces $700 Million Stock Offering" with +55 impact score. Join our Discord community for real-time alerts and discussions.

Latest News

Real Estate +55 EQIX

Equinix Reports Strong Q3 Results, Raises 2026 Guidance, and Announces $700 Million Stock Offering

Equinix reported Q3 revenue of $2.57 billion, up 11% year over year, and net income of $489 million, up 31%. The company raised its 2026 revenue and AFFO-per-share guidance for the third consecutive quarter and projected 2026 cabinet deliveries nearly 40% above prior forecasts, with 3 GW of developable capacity. Equinix filed for a $700 million common stock offering and a shelf registration statement, and agreed to fund electrical grid infrastructure for a Georgia project.

Healthcare +70 PFE

Pfizer Reports Q2 Revenue Growth and Raises Full-Year Outlook

Pfizer reported second-quarter revenue growth of 18% year over year, excluding currency impacts. The company raised the midpoint of its full-year revenue forecast by $500 million. Pfizer is scheduled to release its complete quarterly financial results later this week.

Healthcare +70 INDV

Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals

Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, combining their operations and resources to create a more diversified company focused on central nervous system biopharmaceuticals. The combined company plans to use its broader portfolio of marketed medicines and increased financial flexibility to strengthen its market position and support long-term growth. The article reports no financial terms or stock-price impact.

Load More News